Bivalirudin vs Lanreotide
Overview
Bivalirudin is primarily a cardiovascular peptide, while Lanreotide is used for hormonal.
This page compares Bivalirudin and Lanreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Lanreotide | |
|---|---|---|
| Category | Cardiovascular | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 60-120 mg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | every 4 weeks |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Lanreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Lanreotide: FDA-approved.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Lanreotide is typically dosed at 60-120 mg (every 4 weeks).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Lanreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Lanreotide?
- Bivalirudin is primarily a cardiovascular peptide, while Lanreotide is used for hormonal. Bivalirudin is FDA-approved for one or more indications, whereas Lanreotide is FDA-approved for one or more indications.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- Can you take Bivalirudin and Lanreotide together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Lanreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Lanreotide FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Lanreotide is FDA-approved for one or more indications.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Lanreotide — full monograph: mechanism, research, dosing & references